Established Mabspace Biosciences (Suzhou) (Now renamed as Suzhou Transcenta Therapeutics Co., Ltd.)

Developed the Immune Tolerance Breaking Technology Platform (IMTB)

Established HJB (Hangzhou) Co., Ltd.

Obtained MSB2311 IND clearance from FDA and NMPA

HJB Launched Process and Product Development Center and Manufacturing Facility in Hangzhou

Mabspace & HJB merged to establish Transcenta

In-licensed Blosozumab (TST002)

Obtained MSB0254 IND clearance from NMPA

Obtained Osemitamab (TST001) IND clearance from NMPA and FDA

First patient dosed in Phase I clinical trial of Osemitamab (TST001) in US

Formed collaboration with Merck to co-develop continuous downstreaming manufacturing technology

Formed JV with Alebund for co-development of TST004 for renal disease in China

Obtained TST005 IND clearance from FDA

First patient dosed in Phase I clinical study of Osemitamab (TST001) combined with CAPOX

First patient dosed in global Phase I clinical trial of TST005 in US

FDA Granted ODD to Osemitamab (TST001), for the treatment of G/GEJ Cancer

Held investigator meeting and first patient dosed in Phase IIa clinical trial of Osemitamab (TST001) in China

HKEX Listing (Stock Code: 6628) on Sept 29th

Obtained TST002 IND clearance from NMPA

First patient dosed in Phase Ib clinical trial of MSB0254

Obtained TST005 IND clearance from NMPA

First patient dosed in Phase IIa clinical trial of Osemitamab (TST001) combined with CG for BTC

Global clinical collaboration with BMS to evaluate Osemitamab (TST001) in combination with Opdivo

First patient dosed in China Phase I clinical trial of TST002

Nature Cancer published the study results by Transcenta and Shanghai Jiaotong University scientists on the potential application of TST003 in the treatment of androgen receptor-negative/low

Released Phase I clinical data of Osemitamab (TST001) in combination with CAPOX as the first line treatment of advanced and metastatic G/GEJ cancer at ASCO 2022

Presented the preclinical data of TST004 at the 2022 ISN frontiers meetings of complement related kidney diseases

Presented interim safety and efficacy data of the Osemitamab (TST001) and chemotherapy combination expansion cohort for claudin18.2 positive first line gastric cancer at ESMO congress 2022

Obtained TST003 and TST004 IND clearance from FDA

Obtained TST003 IND clearance from NMPA

Study results of CLDN18.2-targeting Immuno-PET Probe for non-invasive imaging in gastrointestinal tumors have been published on Journal of Pharmaceutical Analysis

First patient dosed in the US Phase I clinical trial of TST003

FDA Granted ODD to Osemitamab (TST001), for the treatment of Pancreatic Cancer

Completed Enrollment in Cohorts C and G of China Phase II Clinical Study of Osemitamab (TST001) in Combination with CAPOX with or without Nivolumab as First-line Treatment of G/GEJ Cancer Patients

Released encouraging Phase I clinical data of TST002 in Chinese patients with reduced bone mineral density

Presented updated data of Osemitamab (TST001) in combination with CAPOX as a first-line treatment of G/GEJ cancer at ASCO and ESMO GI

Received approvals from China CDE, South Korea MFDS and FDA to initiate TranStar 301 global Phase III pivotal trial of Osemitamab (TST001)

Received approval from CDE to initiate Phase II clinical trial of TST002 in patients with reduced bone mineral density